pneumococcal 7-valent conjugate vaccine
Trade name: Prevnar
Vaccineapproved
Approved
Feb 17, 2000
Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children. — Wikipedia
Clinical trial activity
86 trials · 60 clinical orgs · 1 marketing orgs
Phase 1
10
Phase 2
65
Phase 3
54
Phase 4
11
Earliest trial started Mar 1, 1995 (NCT00378417)
Timeline
2000s
- Feb 17, 2000
American Home Products — Earliest FDA Approval
- Feb 17, 2000
American Home Products — NDA Secondary Org
- Feb 17, 2000
American Home Products — NDA Organization
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Chickenpox · Phase 3
- Communicable Diseases · Phase 4
- Diphtheria · Phase 3
- Haemophilus influenzae type b · Phase 3
- Healthy Volunteers · Phase 4
- Hepatitis B · Phase 3
- HIV · Phase 4
- HIV Infections · Phase 3
- Immunosuppression Therapy · Phase 3
- Kidney Diseases · Phase 4
- Measles · Phase 3
- Meningitis · Phase 4
- Meningitis, Meningococcal · Phase 3
- Meningococcal Infections · Phase 3
- Multiple Myeloma · Phase 1/Phase 2
- Mumps · Phase 3
- Neisseria meningitidis · Phase 3
- Otitis Media · Phase 3
- Pertussis Vaccine · Phase 3
- Pneumococcal Infections · Phase 4
- Pneumococcal Vaccines · Phase 4
- Pneumonia · Phase 4
- Pneumonia, Pneumococcal · Phase 4
- Pneumonia, Staphylococcal · Phase 3
- Poliomyelitis · Phase 3
- Primary Immunodeficiency Diseases · Phase 4
- Respiratory Tract Infections · Phase 4
- Rubella · Phase 3
- Streptococcal Infections · Phase 4
- Streptococcus pneumoniae · Phase 3
- Tetanus · Phase 3
- Transplants · Phase 3
- Vaccines · Phase 3
- Whooping Cough · Phase 3
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedFeb 17, 2000
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPneumococcal conjugate vaccine ↗
Also known as
- 7-valent pneumococcal conjugate vaccine
- gsk1024805a
- gsk1024850a
- gsk 1024850a
- heptavalent pneumococcal conjugate vaccine
- pcv7
- pcv-7
- pneumococcal 7-valent conjugate vaccine
- pneumococcal conjugate vaccine
- pneumococcus conjugate vaccine 7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300644 | Phase 2 | Nov 25, 2025 | China National Pharmaceutical Group |
| NCT06800261 | Phase 1 | Apr 30, 2025 | China National Pharmaceutical Group, Government of China |
| NCT06617715 | Phase 3 | Oct 12, 2024 | China National Pharmaceutical Group, Government of China |
| NCT06562790 | Phase 1 | Aug 26, 2024 | GPN Vaccines |
| NCT02961231 | Phase 4 | Nov 1, 2016 | Government of Vietnam, Murdoch University, University of London, University of Nagasaki |
| NCT02892812 | Phase 1 | Sep 1, 2016 | LG, Seoul National University |
| NCT02494999 | Phase 3 | Jun 1, 2016 | Beijing Minhai Biotechnology Co., Ltd, Government of China |
| NCT02736240 | Phase 3 | Apr 1, 2016 | Walvax Biotechnology Co., Ltd. |
| NCT02447432 | Phase 3 | Jun 11, 2015 | GlaxoSmithKline |
| NCT02097472 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | Kenya Medical Research Institute, PATH |
| NCT01983540 | Phase 3 | Oct 1, 2013 | Sanofi |
| NCT01692886 | Phase 3 | Aug 1, 2012 | Pfizer |
| NCT02133469 | N/A | Jun 1, 2012 | Beijing Municipal Health Bureau, Centers for Disease Control and Prevention, China, Government of China |
| NCT01235949 | Phase 4 | Nov 12, 2010 | GlaxoSmithKline |
| NCT01250756 | Phase 4 | Nov 1, 2010 | Pfizer |
| NCT01153893 | Phase 3 | Oct 1, 2010 | GlaxoSmithKline |
| NCT01200368 | Phase 3 | Sep 1, 2010 | Pfizer |
| NCT01119625 | Phase 3 | Jul 1, 2010 | GlaxoSmithKline |
| NCT01030822 | Phase 3 | Apr 1, 2010 | GlaxoSmithKline |
| NCT01135082 | N/A | Apr 1, 2010 | Chulalongkorn University, The HIV Netherlands Australia Thailand Research Collaboration |
Showing 20 of 86 trials
Page 1 / 5
Organizations
Research & Development (60)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 28 | 28 | 3 | 2006 |
| Pfizer | For profit | 22 | 21 | 4 | 1999 |
| Wyeth | For profit | 16 | 0 | 4 | 1995 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 4 | 5 | 1999 |
| Government of China | Government | 4 | 1 | 3 | 2012 |
| Novartis | For profit | 4 | 4 | 2 | 2007 |
| China National Pharmaceutical Group | For profit | 3 | 3 | 3 | 2024 |
| Centers for Disease Control and Prevention (CDC) | Government | 2 | 2 | 1 | 2002 |
| Sanofi | For profit | 2 | 2 | 1 | 2007 |
| University of London | Academic/Hospital | 2 | 0 | 1 | 2003 |
| University of Maryland | Academic/Hospital | 2 | 0 | 2 | 1999 |
| Utrecht University | Academic/Hospital | 2 | 2 | 2 | 2003 |
| Alaska Native Tribal Health Consortium | Government | 1 | 0 | 1 | 2002 |
| Beijing Minhai Biotechnology Co., Ltd | For profit | 1 | 0 | 1 | 2016 |
| Beijing Municipal Health Bureau | Government | 1 | 0 | 1 | 2012 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2002 |
| Centers for Disease Control and Prevention, China | Government | 1 | 1 | 1 | 2012 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| French National Agency for Research on AIDS and Viral Hepatitis | Government | 1 | 1 | 1 | 2003 |
60 organizations
Page 1 / 3
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | NDA2 | Feb 17, 2000 |
| American Home Products | For profit | NDA | Feb 17, 2000 |